Determine HIV 1/2 Ag/Ab Combo on stand #203 at IAS 2009

PR Log (Press Release) – Jun 26, 2009 – Bedford, UK: The new 4th generation rapid HIV diagnostic test – Determine® HIV 1/2 Ag/Ab Combo – from Inverness Medical is capable of detecting HIV infection  several days earlier than HIV antibody only tests and is ideal to help diagnose and screen for early HIV infection. The ability of this test to enhance the diagnosis of those with acute HIV infection will provide additional benefits in HIV prevention programs and ultimately contribute to a reduction in the spread of HIV. Inverness Medical will be showcasing the new Determine Combo test at the International AIDS Society Conference 2009 in Capetown, South Africa, 19-22 July on stand #203.

Determine HIV-1/2 Ag/Ab Combo enables simultaneous separate detection of HIV p24 antigen (Ag) and antibodies (Ab) for HIV-1 and HIV-2 in human serum, plasma, or whole blood. The p24 antigen is produced during the first few weeks of HIV infection and is detectable 7-9 days earlier than the appearance of HIV antibodies. As a result, the p24 antigen is an ideal marker in aiding early HIV diagnosis.

By simultaneously detecting for all known sub types of HIV and HIV-1 p24 antigen, as a CE marked test, Determine HIV-1/2 Ag/Ab Combo increases the ability to detect and diagnose primary HIV infection (2-20 days earlier than HIV antibody only tests, with an average mean of 5 days) and can help healthcare workers across the world diagnose primary infection, prevent mother to child transmission, monitor HIV prevalence and screen blood donations. By understanding their HIV status, individuals are able to gain early access to specific treatment, care and counselling, prevent transmission, and plan for the future.

The first test of its kind for acute HIV infection, Determine HIV 1/2 Ag/Ab Combo provides clear visual results during the patient visit in 20 minutes, with excellent sensitivity of 100% and a specificity of 99.23% and 99.66% for HIV antibodies and HIV-1 p24 antigen respectively. The easy to use, robust format of Determine does not require electricity, water, or the use of bulky laboratory equipment and can be performed in point-of-care settings and remote locations in developing countries where laboratory facilities are limited. This gives significant advantages over lab-based EIA and ELISA 4th generation HIV testing.

For more information about Determine HIV-1/2 Ag/Ab Combo, visit Inverness Medical on stand #203 at the IAS Conference 2009.